Takeda Pharmaceutical Company Limited (NYSE: TAK )’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

European Commission approves Adcetris, Takeda & Pfizer's antibody-drug combo, for frontline Hodgkin lymphoma. Read more here.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shar ...

Enbrel revenues declined 6% to $140 million. Pfizer’s acquisition of Seagen in December 2023 added antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak — to its cancer portfolio.

Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European Commission (EC) approval of Adcetris (brentuximab vedotin) in combination ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris (brentuximab vedotin) as part of a combination treatment for adults with untreated ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with ...